97 related articles for article (PubMed ID: 1801638)
1. Enhancement of nonspecific resistance against microbial infections with special reference to Pseudomonas aeruginosa infection by chemically synthesized lipid A-subunit analogs.
Matsuura M; Homma JY
Antibiot Chemother (1971); 1991; 44():203-8. PubMed ID: 1801638
[No Abstract] [Full Text] [Related]
2. Protective effect of cytokines in mice to Pseudomonas aeruginosa infection.
Nakano M; Onozuka K; Sakamoto K; Nakano Y; Shinomiya H; Saito-Taki T
Antibiot Chemother (1971); 1991; 44():196-202. PubMed ID: 1801637
[No Abstract] [Full Text] [Related]
3. Non-specific protective activity of synthetic lipid A-subunit analogs against microbial infections is influenced by their 2-N- and 3-O-linked acyl substituents in the D-glucosamine backbone.
Ikeda S; Matsuura M; Nakatsuka M; Homma JY; Kiso M; Hasegawa A; Nishimura C
J Clin Lab Immunol; 1990 Aug; 32(4):177-81. PubMed ID: 1966934
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of nonspecific resistance to microbial infections of synthetic lipid A-subunit analogues of GLA-27 modified at the C1 position of the glucosamine backbone.
Nakatsuka M; Ikeda S; Kumazawa Y; Matsuura M; Nishimura C; Homma JY; Kiso M; Hasegawa A
Int J Immunopharmacol; 1990; 12(6):599-603. PubMed ID: 1703131
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of protective effects of chitin, chitosan, and N-acetyl chitohexaose against Pseudomonas aeruginosa and Listeria monocytogenes infections in mice.
Okawa Y; Kobayashi M; Suzuki S; Suzuki M
Biol Pharm Bull; 2003 Jun; 26(6):902-4. PubMed ID: 12808311
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of nonspecific resistance to bacterial infections and tumor regressions by treatment with synthetic lipid A-subunit analogs. Critical role of N- and 3-O-linked acyl groups in 4-O-phosphono-D-glucosamine derivatives.
Nakatsuka M; Kumazawa Y; Matsuura M; Homma JY; Kiso M; Hasegawa A
Int J Immunopharmacol; 1989; 11(4):349-58. PubMed ID: 2777430
[TBL] [Abstract][Full Text] [Related]
7. [CULTURE CHARACTERISTICS AND THE ANTIBIOGRAM OF STRAINS OF PSEUDOMONAS AERUGINOSA ISOLATED FROM PATHOLOGICAL PRODUCTS].
PORTOLES A; PEREZ URENA MT
Rev Clin Esp; 1964 Jun; 93():373-7. PubMed ID: 14183646
[No Abstract] [Full Text] [Related]
8. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
Moriyama K; Wiener-Kronish JP; Sawa T
Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
[TBL] [Abstract][Full Text] [Related]
9. Antiherpes activity of chemically synthesized lipid A-subunit analogue GLA-60 in immunosuppressed mice.
Ikeda S; Tominaga T; Nishimura C; Homma JY; Kiso M; Hasegawa A
Antiviral Res; 1989; 11(4):173-80. PubMed ID: 2545164
[TBL] [Abstract][Full Text] [Related]
10. Control of Pseudomonas aeruginosa infection in mice by chlorine treatment of drinking water.
Homberger FR; Pataki Z; Thomann PE
Lab Anim Sci; 1993 Dec; 43(6):635-7. PubMed ID: 8158997
[No Abstract] [Full Text] [Related]
11. Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanisms.
Naito K; Arakawa H; Watanabe Y; Okura A; Ishizuka M; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1987 Apr; 40(4):547-54. PubMed ID: 3034847
[TBL] [Abstract][Full Text] [Related]
12. Provocation of pseudomoniasis with cyclophosphamide in mice.
Urano T; Maejima K
Lab Anim; 1978 Jul; 12(3):159-61. PubMed ID: 102866
[TBL] [Abstract][Full Text] [Related]
13. Respiratory infection of cyclophosphamide-treated mice with Pseudomonas aeruginosa.
Rowatt JD; Hill JO; Lundgren DL
Exp Lung Res; 1983 Dec; 5(4):305-16. PubMed ID: 6420143
[TBL] [Abstract][Full Text] [Related]
14. Studies of lung infections caused by Pseudomonas aeruginosa in mice treated with cyclophosphamide.
Mayer P; Walzl H
Infection; 1983; 11(2):87-96. PubMed ID: 6408008
[TBL] [Abstract][Full Text] [Related]
15. Aminoarabinosylation of Lipid A Is Critical for the Development of Colistin Resistance in Pseudomonas aeruginosa.
Lo Sciuto A; Imperi F
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263076
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of resistance to bacterial infection in mice by vitamin B2.
Araki S; Suzuki M; Fujimoto M; Kimura M
J Vet Med Sci; 1995 Aug; 57(4):599-602. PubMed ID: 8519884
[TBL] [Abstract][Full Text] [Related]
17. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
18. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
[TBL] [Abstract][Full Text] [Related]
19. [Occurrence in various organic matter and chemo-antibiotic resistance of Pseudomonas aeruginosa isolated in Umbria 1979-1981].
Bianchi P; Carotti A; Martinelli P; Panella V; Frongillo RF
Nuovi Ann Ig Microbiol; 1985; 36(2):127-37. PubMed ID: 3939151
[No Abstract] [Full Text] [Related]
20. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa.
Price BM; Galloway DR; Baker NR; Gilleland LB; Staczek J; Gilleland HE
Infect Immun; 2001 May; 69(5):3510-5. PubMed ID: 11292786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
